The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis
T D Sandahl, R McGrail, H J Møller, E Reverter, Søren Møller, F Turon, V Hernández-Gea, F Bendtsen, H Vilstrup, J C Garcia-Pagan, H. Grønbæk
Dyk ned i forskningsemnerne om 'The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis'. Sammen danner de et unikt fingeraftryk.